All In Biotech

Drug Trial Radar · NCT03969212

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

A Phase IIIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Efficacy Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza From Otherwise Healthy Patients to Household Contacts

Last checked: Nov 20, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,138 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,138

Actual

Start

Oct 10, 2019

Primary completion

May 10, 2024

Study completion May 10, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screening. Their households are enrolled within 24 hours of randomization if at least 1 household contacts (HHC) have not received influenza vaccine within 6 months of screening and if all HHC screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs, obtained from both IP and HHC up to 9 (+/-1) days post IP randomization, and through the assessment of symptoms.

Conditions

  • Influenza

Interventions

  • Baloxavir MarboxilDrug

    IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.

  • PlaceboDrug

    IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of HHCs With Virological Influenza Transmission by Day 5Time frame: Baseline (Day 1) to Day 5

Locations

142 sites in 16 countries. Site status is shown where the registry gives one.

  • Cahaba Research, Inc.

    Birmingham, Alabama

  • Cahaba Research, Inc

    Pelham, Alabama

  • Precision Trials

    Phoenix, Arizona

  • Hope Clinical Research

    Canoga Park, California

  • Long Beach Clinical Trials

    Long Beach, California

  • Downtown LA Research Center

    Los Angeles, California

  • Probe Clinical Research

    Riverside, California

  • MD Strategies Research Centers

    San Diego, California

  • Cherry Creek Family Practice

    Denver, Colorado

  • Proactive Clinical Research, LLC

    Fort Lauderdale, Florida

  • Helios Clinical Research, Inc (former Ventavia Research Group)

    Kissimmee, Florida

  • South Florida Research Center, Inc.

    Miami, Florida

  • Cordova Research Institute, LLC

    Miami, Florida

  • Research Institute of South Florida Inc

    Miami, Florida

  • Kendall South Medical Center Inc.

    South Miami, Florida

  • Agile Clinical Research Trials

    Atlanta, Georgia

  • Clinical Research Prime

    Idaho Falls, Idaho

  • Mishawaka Osteopathic Clinic

    Mishawaka, Indiana

  • Washington University School of Medicine

    St Louis, Missouri

  • Mercury Street Medical Group

    Butte, Montana

  • Montana Medical Research LLC

    Missoula, Montana

  • Accent Clinical Trials

    Las Vegas, Nevada

  • Excel Clinical Research

    Las Vegas, Nevada

  • OnSite Clinical Solutions LLC

    Charlotte, North Carolina

  • Burke Primary Care

    Morganton, North Carolina

  • Hometown Urgent Care and Occupational Health - Springdale

    Cincinnati, Ohio

  • Tristar Clinical Investigations

    Philadelphia, Pennsylvania

  • Frontier Clinical Research

    Scottdale, Pennsylvania

  • Frontier Clinical Research

    Smithfield, Pennsylvania

  • Frontier Clinical Research

    Smithfield, Pennsylvania

  • Jedda Enterprises dba Galen Clinical Research

    Greer, South Carolina

  • AFC Urgent Care-Gunbarrell

    Chattanooga, Tennessee

  • Helios Clinical Research, Inc (former Ventavia Research Group)

    Jackson, Tennessee

  • City Doc Urgent Care-Dallas/Ft. Worth

    Dallas, Texas

  • Southwest Family Medicine Associates

    Dallas, Texas

  • Premier Pulmonary Critical Care and Sleep Medicine

    Denison, Texas

  • Pioneer Research Solutions

    Houston, Texas

  • Vilo Research Group

    Houston, Texas

  • Fairway Medical Clinic

    Houston, Texas

  • Mercury Clinical Research

    Houston, Texas

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.